Lewis R J, Singh O M, Smith C V, Skarzynski T, Maxwell A, Wonacott A J, Wigley D B
Laboratory of Molecular Biophysics, University of Oxford, UK.
EMBO J. 1996 Mar 15;15(6):1412-20.
This study describes the first crystal structures of a complex between a DNA topoisomerase and a drug. We present the structures of a 24 kDa N-terminal fragment of the Escherichia coli DNA gyrase B protein in complexes with two different inhibitors of the ATPase activity of DNA gyrase, namely the coumarin antibiotic, novobiocin, and GR122222X, a member of the cyclothialidine family. These structures are compared with the crystal structure of the complex with an ATP analogue, adenylyl-beta-gamma-imidodiphosphate (ADPNP). The likely mechanism, by which mutant gyrase B proteins become resistant to inhibition by novobiocin are discussed in light of these comparisons. The three ligands are quite dissimilar in chemical structure and bind to the protein in very different ways, but their binding is competitive because of a small degree of overlap of their binding sites. These crystal structures consequently describe a chemically well characterized ligand binding surface and provide useful information to assist in the design of novel ligands.
本研究描述了DNA拓扑异构酶与一种药物复合物的首个晶体结构。我们展示了大肠杆菌DNA促旋酶B蛋白24 kDa N端片段与两种不同的DNA促旋酶ATP酶活性抑制剂形成复合物的结构,这两种抑制剂分别是香豆素抗生素新生霉素和环硫噻吨家族成员GR122222X。将这些结构与该蛋白与ATP类似物腺苷酰-β-γ-亚氨基二磷酸(ADPNP)形成复合物的晶体结构进行了比较。基于这些比较,讨论了突变型促旋酶B蛋白对新生霉素抑制产生抗性的可能机制。这三种配体的化学结构差异很大,以非常不同的方式与蛋白质结合,但由于它们的结合位点有小程度的重叠,所以它们的结合具有竞争性。因此,这些晶体结构描述了一个化学特征明确的配体结合表面,并为协助设计新型配体提供了有用信息。